Exciting Developments from TScan Therapeutics
TScan Therapeutics, Inc. (NASDAQ: TCRX), based in Waltham, Massachusetts, is a pioneering clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell therapies. These innovations are aimed at providing advanced treatment options for cancer patients. Recently, TScan announced the acceptance of three significant abstracts that will be presented as posters during the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
Poster Presentation Highlights
The SITC annual meeting promises to deliver groundbreaking insights into cancer treatment. TScan's research is set to be showcased in three poster presentations, highlighting the company’s commitment to understanding and combating cancer through innovative TCR-T therapy.
Discovery of MAGE-A4-specific TCR-T Therapy Candidate
The first poster will focus on the discovery of a MAGE-A4-specific TCR-T therapy candidate designed for the multiplex treatment of solid tumors. This presentation is authored by a collaborative team including Rutuja Kulkarni, Akshat Sharma, and others. The session is scheduled for Friday, with viewing times from 9:00 a.m. to 7:00 p.m. Central Time at the George R. Brown Convention Center.
Customized TCR-T Cell Therapy Models
The second presentation will delve into preclinical models for T-Plex, a customized multiplexed TCR-T cell therapy that addresses intra-tumor antigen and HLA heterogeneity. Authors Maytal Bowman and Amanda Kordosky lead this insightful research, with their session also set for Friday in the same timeframe and location.
Target Agnostic Platform Development
Finally, the third poster will discuss the development of a target agnostic platform designed to evaluate the reactivity of TCR-engineered T cell therapies to primary human tissues. This session will feature contributions from prominent researchers such as Sveta Padmanabhan and Shubhangi Kamalia. Scheduled for Saturday, the session runs from 9:00 a.m. to 8:30 p.m. Central Time, continuing the tradition of showcasing vibrant research at this significant gathering.
Access to Presentation Materials
For those interested in further details, a copy of the presentation materials will be available in the Publications section of TScan's website after the event concludes. This resource will provide ongoing insights into TScan's research advancements and commitments within the field.
About TScan Therapeutics, Inc.
TScan operates at the frontier of cancer immunotherapy, focusing heavily on the development of TCR-T therapies tailored for various cancer types. Their lead candidates, TSC-100 and TSC-101, are under evaluation for treating patients with hematologic malignancies. These therapies show potential in preventing relapse after allogeneic hematopoietic cell transplantation. Moreover, TScan is triumphantly expanding its ImmunoBank, a repository of TCRs that can recognize a broad range of cancer targets associated with multiple HLA types.
Company Contact Information
For inquiries, Heather Savelle, VP of Investor Relations at TScan, can be reached at 857-399-9840 or via email. Additional communications can be addressed to Maghan Meyers at Argot Partners, with direct contact available through email as well.
Frequently Asked Questions
What is TScan Therapeutics known for?
TScan Therapeutics specializes in developing innovative TCR-engineered T cell therapies aimed at treating cancer.
When is TScan presenting at the SITC Annual Meeting?
TScan will present its posters at the SITC Annual Meeting from November 6 to November 10, with specific sessions on November 8 and 9.
What topics will TScan's presentations cover?
The presentations will explore advancements in TCR-T therapies, including a specific candidate for solid tumors and the development of a target-agnostic platform.
Where can I find the presentation materials after the event?
A copy of the materials will be available in the Publications section of TScan's website after the annual meeting.
How can I contact TScan Therapeutics for more information?
For more information, reach out to Heather Savelle or Maghan Meyers via the provided contact details in the article.
